On April 4th, STENOCARE announced that the innovative ASTRUM 10-10 has obtained for approval for reimbursement in Germany through major health insurance providers. Starting in April 2025, approximately 14 million insured individuals will be eligible for 100% reimbursement when treated with ASTRUM 10-10.
Analyst Group’s View of the News
On the global medical cannabis market, whether patients pay for STENOCARE’s medical cannabis products out-of-pocket or receive subsidies from local governments or insurance providers varies significantly between markets. The differing subsidy structures may result in varying prescription rates, as patients in countries with higher subsidies are more likely to purchase STENOCARE’s products.
In the German market, the products are not subsidized by the government; however, certain products are reimbursed by insurance providers. This reimbursement structure is expected to increase patient access. STENOCARE’s first product available in Germany, AD 10-10 STENOCARE Extrakt, was reimbursed by insurance providers, and as of April 2025, the Astrum oil is also approved for reimbursement.
The Company’s premium product, Astrum oil, is regarded as a key growth driver for the year ahead. The product differentiates STENOCARE as a first mover in the next generation of medical cannabis, offering improved, uniform, and faster uptake in the bloodstream.
Germany represents the largest medical cannabis market in Europe, with total expected sales of EUR 1bn in year 2027. Therefore, sales of Astrum oil in the German market are viewed as a critical factor for revenue expansion over the coming years. The secured reimbursement by two of the leading German health insurance providers, Techniker Krankenkasse and AOK Rheinland, makes approximately 14 million individuals eligible for coverage, marking a significant milestone toward realizing the anticipated growth.
In conclusion, Analyst Group identifies Astrum oil as the primary growth driver in the upcoming year, as it differentiates the Company from competitors through superior absorption and product consistency. The reimbursement approval from major health insurance providers for the Company’s Astrum oil is viewed as a pivotal step toward accelerating product growth in the largest European market.
